8 completed, 3 unknown, 2 not yet recruiting, 2 terminated. 9 Phase 2, 6 Not applicable, 3 Phase 1, 3 Phase 3.
Follow Serine: new trials by email Literature Review of Serine trials Research Report on Serine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Serine Supplementation to Protect Vision in MacTel L-serine, Placebo - Macular Telangiectasia Type 2 (MacTel) | Phase 3 | Not yet recruiting | The Lowy Medical Research Institute Limited | 120 | 2026-09-01 | 2026-01-15 |
| Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Serine/Glycine-Restricted Diet, CAPOX Chemotherapy, PD-1 Inhibitor - Locally Advanced Rectal Cancer (LARC) | Phase 1 / Phase 2 | Not yet recruiting | Xuelei Ma MD | 140 | 2026-08-31 | 2026-09-09 |
| TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders L-serine, Maltodextrin (Placebo) - GRIN-related Disorders, GRIN1 | Phase 3 | Recruiting | Meyer Children's Hospital IRCCS | 40 | 2025-08-29 | 2026-01-29 |
| Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine, Placebo - Visceral Obesity, Non-alcoholic Fatty Liver | Not applicable | Completed | Fundació Eurecat | 50 | 2024-06-07 | 2025-04-17 |
| Hereditary Sensory Neuropathy Serine Trial L-serine, Placebo - Hereditary Sensory Neuropathy Type I | Phase 2 | Unknown | University College, London | 50 | 2023-08-21 | 2023-11-02 |
| Effect of a Multi-ingredient on Visceral Adiposity and Non-alcoholic Fatty Liver Disease in Individuals With Abdominal Obesity Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine, Placebo - Visceral Obesity, Non-Alcoholic Fatty Liver Disease | Not applicable | Completed | Fundació Eurecat | 20 | 2023-05-01 | 2024-02-23 |
| Serine and Fenofibrate Study in Patients With MacTel Type 2 Serine, Fenofibrate - Macular Telangiectasia Type 2 | Phase 2 | Completed | The Lowy Medical Research Institute Limited | 89 | 2022-04-07 | 2026-09-21 |
| Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy L-serine - GRIN Related Disorders | Not applicable | Unknown | Fundació Sant Joan de Déu | 20 | 2020-07-30 | 2020-11-30 |
| Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS) L-Serine - Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Terminated | Elijah W. Stommel | 43 | 2018-10-24 | 2025-04-20 |
| Phase IIa L-serine Trial for eAD L-Serine, Placebo Gummy - Alzheimer Disease | Phase 2 | Terminated | Aleksandra Stark | 29 | 2017-03-01 | 2024-07-03 |
| Short Term Dietary Serine Supplementation and Circulating Serine Levels L-serine - Serine | Not applicable | Withdrawn | Massachusetts General Hospital | 2016-09-01 | 2016-09-16 | |
| L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1 L-serine, placebo - Hereditary Sensory and Autonomic Neuropathy Type I | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 18 | 2013-09-01 | 2018-09-12 |
| Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet - Liver Cirrhosis | Phase 2 | Completed | Bausch Health Americas, Inc. | 420 | 2013-06-01 | 2019-10-23 |
| Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. ReConnect (NADH plus CoQ10), placebo - Chronic Fatigue Syndrome | Phase 2 / Phase 3 | Completed | Hospital Universitari Vall d'Hebron Research Institute | 80 | 2013-01-01 | 2015-02-19 |
| Determining the Safety of L-serine in ALS L-Serine - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Unknown | Phoenix Neurological Associates, LTD | 20 | 2013-01-01 | 2015-07-30 |
| Vitamin B6 Dependence of One-Carbon Metabolism Arm 1 glycine and leucine, Arm 2 Intervention of Serine and methionine infusion - Vitamin B6 Deficiency | Not applicable | Completed | University of Florida | 45 | 2008-01-01 | 2013-03-27 |
| Effect of Betaine, Serine and Folic Acid on Vascular Function in Healthy Volunteers supplementation with betaine, serine, and folic acid - Healthy, Cardiovascular Diseases | Not applicable | Completed | Wageningen Centre for Food Sciences | 40 | 2002-08-01 | 2005-08-18 |
Amyotrophic Lateral Sclerosis (2) · Fatty Liver (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Non-alcoholic Fatty Liver Disease (2) · Obesity, Abdominal (2) · Alzheimer Disease (1) · Cardiovascular Diseases (1) · Disease (1) · Epilepsy (1) · Fatigue (1) · Fatigue Syndrome, Chronic (1) · Hypertension (1) · Liver Cirrhosis (1) · Neurodevelopmental Disorders (1) · Pain (1)
Fundació Eurecat (2) · Massachusetts General Hospital (2) · The Lowy Medical Research Institute Limited (2) · Aleksandra Stark (1) · Bausch Health Americas, Inc. (1) · Elijah W. Stommel (1) · Fundació Sant Joan de Déu (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · Meyer Children's Hospital IRCCS (1) · Phoenix Neurological Associates, LTD (1) · University College, London (1) · University of Florida (1) · Wageningen Centre for Food Sciences (1) · Xuelei Ma MD (1)
United States (8) · Spain (4) · United Kingdom (3) · Netherlands (2) · Australia (1) · China (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Russia (1)
Aleksandra C Stark, MD (1) · Antoni Caimari, PhD (1) · Elijah W Stommel, MD,PHD (1) · Florian S Eichler, MD (1) · Geoffrey A Walford, MD (1) · James Joffrion (1) · Jesse F Gregory, PhD (1) · Jose Alegre-Martin, MD, PhD (1) · Mari A Gantner, PhD (1) · Petra Verhoef, PhD (1) · Todd D Levine, MD (1)
PMID 18029478, PMID 19158217, PMID 19515736, PMID 21430249, PMID 25386668, PMID 25527663, PMID 26212172, PMID 26765812, PMID 26962179, PMID 30626650, PMID 35750249, PMID 37467180, PMID 42231561, PMID 42660511